COMPANY

Tune Therapeutics

Profile checked Oct 10, 2026

Keywords: Chronic Hep B Chronic Hepatitis b Chronic Hepatitis HBV Tune-401

Raises and deals from press releases

Raise Series B · more than $175M · announced Jan 13, 2025 Company release ↗
Source quote
- Jan 13, 2025 · Company release ↗
  “Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs”

Raises announced in these releases: $175M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Jan 13, 2025 Raise Private equity round — Series B: $175M (total, as published), announced Jan 13, 2025. Source: company's own press page. source ↗
Jan 13, 2025 Raise Series B · more than $175M source ↗
Nov 29, 2024 Trial start 1: Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B source ↗

Jun 28, 2028 (ESTIMATED) · 1 · Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B · NCT06671093

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $175.0M. Last 2 years.

Jan 13, 2025 Private equity round — Series B: $175M (total, as published), announced Jan 13, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06671093	Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B	1	Recruiting	Nov 29, 2024	Jun 28, 2028 (estimated)